HeartSciences Inc. (HSCS) Form 8-K — Nov 19, 2026
HeartSciences entered into an Equity Distribution Agreement with Maxim Group LLC on November 18, 2026, establishing an at-the-market program for up to $50,000,000 of common stock off its S-3 shelf declared effective November 17, 2026. Because HeartSciences is subject to General Instruction I.B.6 of Form S-3 (non-affiliate float under $75 million), the prospectus supplement filed November 19, 2026 covers only $3,077,649 of sales, despite the $50 million program size. Maxim earns a 2.5% commission on sales while the I.B.6 limit applies (2.0% thereafter), plus up to $15,000 in legal expense reimbursement and $5,000 per Bringdown Date.
Key figures
- Gross Proceeds
- 50000000
- Shelf capacity
- $200,000,000
- Bringdown date fee
- $5,000
- Commission pct standard
- 2.0%
- Legal fee reimbursement
- $15,000
- Commission pct baby shelf
- 2.5%
- Immediately available amount
- $3,077,649
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.